COVID-19
Figure 2: Biological versus non-biological drugs as a percentage of the pipeline, 1995–2019 Non-biotech
Biotech
100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0%
part – the plunger rod that does not contact the drug – for a connected device. Synnect also provides advanced technological features in comparison with other connected devices; by using BLE to transmit injection data – time and volume – via a smart device app to a secure cloud, Synnect accurately and continuously measures the injected volume. This feature allows Synnect to report a partial dosing, rather than just reporting end of injection, which is the common option for the majority of connected drug-delivery devices. The cloud-available data supports enhanced control over the study by the monitoring staff. In addition, Synnect offers valuable features, such as providing administration alerts and reminders, as well as instructions for use.
Positive effects for clinical trials When it comes to clinical trials of injectable drugs, the route for enhanced patients’ convenience does not stop at connected drug-delivery devices, as clinic visits are not the only cause for inconvenience. Many patients suffer from needle phobia, perceiving the pain of injection harder than it actually is. Needle phobia is present in over 20% of adult patients, and its rate in children
90 | Outsourcing in Clinical Trials Handbook
and adolescents is even higher. Therefore, many patients might feel inconvenienced to participate in a clinical trial of an injectable drug. For this reason, user-friendly injection devices should be used as part of clinical trials – DALI’s SAN product line of safe-automatic needles is easy to use and compatible with a variety of primary containers, hides the needle throughout the entire injection process and helps overcome needle phobia. The combination of a connected drug-delivery device with a user-friendly injection device provides a superior user-experience, enabling care at home with maximum comfort. Improved patient convenience would reduce the clinical trials dropout rate, helping pharma companies shorten the time-to-market and minimise costs. As the entire world is currently facing the
Covid-19 pandemic, the significance of remote care is emphasised, in addition to the patients’ convenience; home care is also useful for protecting patients at risk, by enabling them to get their medication treatment at home instead of at the clinic. Digital health, in the form of connected drug-delivery devices, enables improvement clinical trials’ effectiveness, while protecting patients’ health simultaneously. ●
Percentage
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120
